Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Pharvaris N.V.

CIK 1830487Updated Nov 17, 2026

Name history
Pharvaris, B.V. · through Feb 4, 2021

PHVS price & chart

Provider market data

Loading TradingView…

NASDAQ:PHVS on TradingView ↗

TradingView · Data may be delayed

About the company

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.

6-K · 2026-11-12 · 0001193125-26-456847

Company description from the cited filing.

Financials

FY 2025 · EUR
Revenue— · FY 2025
Net income— · FY 2025
Assets—EUR · FY 2025
Cash— · FY 2025
Operating income-173,711,496EUR · FY 2025
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

Diluted EPS-2.97EUR/shares · FY 2025
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemQ2 2025Q2 2024Q2 2023Q2 2022Q2 2021FY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Profit or LossEUR-45,480,686
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

-29,731,073
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

-21,897,873
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

-12,621,068
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

-15,202,773
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

-175,699,397
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

-134,221,527
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

-100,875,068
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

-76,332,557
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

Additional Financial Items
AdjustmentsForCurrentTaxOfPriorPeriodEUR48,591
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

-290
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

0
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

——-1,052,878
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

98,564
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

-2,819,253
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

—
AdjustmentsForDecreaseIncreaseInTradeAccountReceivableEUR—————-331,339
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

-34,316
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

-41,051
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

317,612
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

AdjustmentsForFinanceCostsEUR————————39,254
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

AdjustmentsForIncomeTaxExpenseEUR—————-2,168,735
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

-2,767,247
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

-1,108,410
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

-182,824
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

AdjustmentsForSharebasedPaymentsEUR—————19,050,394
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

16,208,533
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

10,663,226
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

11,349,200
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

AdjustmentsForUnrealisedForeignExchangeLossesGainsEUR—————11,742,407
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

-7,329,038
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

2,794,435
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

-11,100,392
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseEUR10,765,189
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

11,314,067
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

7,773,430
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

7,660,133
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

4,664,726
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

45,344,598
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

47,124,638
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

31,338,590
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

29,339,034
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR—————219,013
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

159,657
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

220,507
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

119,527
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

ProceedsFromIssuingSharesEUR————————9,609,865
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ2 2025Q2 2024Q2 2023Q2 2022Q2 2021FY 2025FY 2024FY 2023FY 2022
Additional Financial Items
ApplicableTaxRatenumber0.26
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

0.26
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

0.26
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

0.26
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

—0.26
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

0.26
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

0.26
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

0.26
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

AverageEffectiveTaxRatenumber—————-0.01
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

-0.01
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

-0.01
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

-0.01
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

BasicEarningsLossPerShareEUR/shares-0.83
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

-0.55
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

-0.63
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

-0.38
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

-0.46
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

-2.97
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

-2.48
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

-2.63
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

—
CurrentTaxExpenseIncomeEUR157,772
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

70,623
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

94,178
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

2,741,102
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

2,965
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

1,087,278
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

1,033,115
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

473,623
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

757,413
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

DepreciationRightofuseAssetsEUR—————229,203
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

174,799
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

197,770
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

114,020
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

DilutedEarningsLossPerShareEUR/shares-0.83
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

-0.55
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

-0.63
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

-0.38
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

-0.46
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

-2.97
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

-2.48
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

-2.63
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

—
EmployeeBenefitsExpenseEUR15,127,267
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

10,858,498
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

7,978,587
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

6,886,187
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

3,555,390
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

58,894,977
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

46,650,892
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

32,446,666
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

26,819,346
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR—————11,200,000
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

10,500,000
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

6,200,000
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

7,590,041
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpenseEUR10,765,189
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

11,314,067
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

7,773,430
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

7,660,133
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

4,664,726
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

45,344,598
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

47,124,638
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

31,338,590
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

29,339,034
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

IncomeTaxExpenseContinuingOperationsEUR202,782
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

70,623
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

94,178
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

2,741,102
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

2,965
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

1,987,901
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

1,825,024
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

1,048,805
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

679,087
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

InterestExpenseEUR————————16,105
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

InterestExpenseOnLeaseLiabilitiesEUR—————428,846
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

500,161
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

15,803
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

41,633
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

OtherEmployeeExpenseEUR72,108
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

0
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

———630,805
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

———
OtherFinanceCostEUR38,131
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

9,803
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

4,879
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

550
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

3,021
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

172,861
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

46,914
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

20,475
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

23,149
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

ProfessionalFeesExpenseEUR1,686,774
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

2,155,727
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

1,294,705
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

911,170
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

324,793
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

8,616,327
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

7,757,750
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

4,689,462
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

3,972,771
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

ProfitLossBeforeTaxEUR—————-173,711,496
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

-132,396,503
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

-99,826,263
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

-75,653,470
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

ProfitLossFromOperatingActivitiesEUR-45,277,904
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

-29,660,450
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

-21,803,695
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

-9,879,966
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

-15,199,808
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

-173,711,496
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

-132,396,503
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

-99,826,263
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

-75,653,470
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

ResearchAndDevelopmentExpenseEUR29,607,908
Source

6-K · 2025-08-12 · 0000950170-25-107316

2025-04-01 to 2025-06-30

23,067,934
Source

6-K · 2025-08-12 · 0000950170-25-107316

2024-04-01 to 2024-06-30

14,681,935
Source

6-K · 2024-08-14 · 0000950170-24-096640

2023-04-01 to 2023-06-30

13,721,637
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

8,060,599
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

124,478,334
Source

20-F · 2026-04-02 · 0001830487-26-000013

2025-01-01 to 2025-12-31

98,563,529
Source

20-F · 2025-04-07 · 0000950170-25-051347

2024-01-01 to 2024-12-31

65,575,030
Source

20-F · 2024-04-10 · 0000950170-24-043358

2023-01-01 to 2023-12-31

57,375,574
Source

20-F · 2023-04-05 · 0000950170-23-011842

2022-01-01 to 2022-12-31

ProfitLossAttributableToOwnersOfParent———
Source

6-K · 2023-08-07 · 0000950170-23-038727

2023-04-01 to 2023-06-30

—
Source

6-K · 2023-08-07 · 0000950170-23-038727

2022-04-01 to 2022-06-30

—
Source

6-K · 2022-09-12 · 0001193125-22-242389

2021-04-01 to 2021-06-30

————

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

phvs-ex99_1.htm · 6-K · 2026-11-12

Exhibit 99.1 Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update • Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027 • Topline data from part 1 of CREAATE, a pivotal Phase 3 study evaluating deucrictibant XR for the prophylaxis of AAE-C1INH attacks, expected in 1Q2027; enrollment ongoing in part 2 of CREAATE evaluating deucrictibant IR for the on-demand treatment of AAE-C1INH attacks • Preparation of NDA dossier of deucrictibant XR…

6-K · 2026-11-12 · 0001193125-26-456847

Read attachment ↗
phvs-ex99_2.htm · 6-K · 2026-11-12

Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes thereto, for the three and nine months ended September 30, 2026 and 2025 included as Exhibit 99.3 to th…

6-K · 2026-11-12 · 0001193125-26-456847

Read attachment ↗
phvs-ex99_1.htm · 6-K · 2026-09-08

September 8, 2026 CHAPTER-3 Topline Data This presentation includes data for an investigational product not yet approved by regulatory authorities. Exhibit 99.1 Disclaimer This Presentation contains certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, without …

6-K · 2026-09-08 · 0001193125-26-384472

Read attachment ↗
phvs-ex99_1.htm · 6-K · 2026-09-08

Exhibit 99.1 Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks • Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE • 87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2 • All secondary efficacy endpoints met with statistical significance • Well-tolerated safety profile of deucrictibant XR d…

6-K · 2026-09-08 · 0001193125-26-384339

Read attachment ↗
phvs-ex99_1.htm · 6-K · 2026-08-12

Exhibit 99.1 Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update • Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 • Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA validated by the EMA in July 2026 • Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks • Strong financ…

6-K · 2026-08-12 · 0001193125-26-345702

Read attachment ↗
phvs-ex99_2.htm · 6-K · 2026-08-12

Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes thereto, for the three and six months ended June 30, 2026 and 2025 included as Exhibit 99.3 to the Repo…

6-K · 2026-08-12 · 0001193125-26-345702

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.